Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel,
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Anais brasileiros de dermatologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000200221 |
Resumo: | Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences. |
id |
SBD-1_17c91635f4377e8fb407d61a523960e7 |
---|---|
oai_identifier_str |
oai:scielo:S0365-05962020000200221 |
network_acronym_str |
SBD-1 |
network_name_str |
Anais brasileiros de dermatologia (Online) |
repository_id_str |
|
spelling |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel,Antineoplastic agentsAntineoplastic agents, immunologicalDermatologyDrug-related side effects and adverse reactionsMedical oncologyMolecular targeted therapyAbstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.Sociedade Brasileira de Dermatologia2020-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000200221Anais Brasileiros de Dermatologia v.95 n.2 2020reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1016/j.abd.2020.01.001info:eu-repo/semantics/openAccessCury-Martins,JadeEris,Adriana Pessoa MendesAbdalla,Cristina Martinez ZugaibSilva,Giselle de BarrosMoura,Veronica Paula Torel deSanches,Jose Antonioeng2020-07-03T00:00:00Zoai:scielo:S0365-05962020000200221Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2020-07-03T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false |
dc.title.none.fl_str_mv |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
title |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
spellingShingle |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, Cury-Martins,Jade Antineoplastic agents Antineoplastic agents, immunological Dermatology Drug-related side effects and adverse reactions Medical oncology Molecular targeted therapy |
title_short |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
title_full |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
title_fullStr |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
title_full_unstemmed |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
title_sort |
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel, |
author |
Cury-Martins,Jade |
author_facet |
Cury-Martins,Jade Eris,Adriana Pessoa Mendes Abdalla,Cristina Martinez Zugaib Silva,Giselle de Barros Moura,Veronica Paula Torel de Sanches,Jose Antonio |
author_role |
author |
author2 |
Eris,Adriana Pessoa Mendes Abdalla,Cristina Martinez Zugaib Silva,Giselle de Barros Moura,Veronica Paula Torel de Sanches,Jose Antonio |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Cury-Martins,Jade Eris,Adriana Pessoa Mendes Abdalla,Cristina Martinez Zugaib Silva,Giselle de Barros Moura,Veronica Paula Torel de Sanches,Jose Antonio |
dc.subject.por.fl_str_mv |
Antineoplastic agents Antineoplastic agents, immunological Dermatology Drug-related side effects and adverse reactions Medical oncology Molecular targeted therapy |
topic |
Antineoplastic agents Antineoplastic agents, immunological Dermatology Drug-related side effects and adverse reactions Medical oncology Molecular targeted therapy |
description |
Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000200221 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000200221 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.abd.2020.01.001 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
dc.source.none.fl_str_mv |
Anais Brasileiros de Dermatologia v.95 n.2 2020 reponame:Anais brasileiros de dermatologia (Online) instname:Sociedade Brasileira de Dermatologia (SBD) instacron:SBD |
instname_str |
Sociedade Brasileira de Dermatologia (SBD) |
instacron_str |
SBD |
institution |
SBD |
reponame_str |
Anais brasileiros de dermatologia (Online) |
collection |
Anais brasileiros de dermatologia (Online) |
repository.name.fl_str_mv |
Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD) |
repository.mail.fl_str_mv |
abd@sbd.org.br||revista@sbd.org.br |
_version_ |
1752126423844257792 |